KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Revenue (2016 - 2025)

Travere Therapeutics' Revenue history spans 13 years, with the latest figure at $129.7 million for Q4 2025.

  • For Q4 2025, Revenue rose 73.41% year-over-year to $129.7 million; the TTM value through Dec 2025 reached $365.9 million, up 56.91%, while the annual FY2025 figure was $490.7 million, 110.45% up from the prior year.
  • Revenue reached $129.7 million in Q4 2025 per TVTX's latest filing, up from $40.0 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $129.7 million in Q4 2025 to a low of $23.4 million in Q1 2022.
  • Average Revenue over 5 years is $53.2 million, with a median of $45.1 million recorded in 2023.
  • Peak YoY movement for Revenue: plummeted 50.61% in 2022, then surged 111.49% in 2025.
  • A 5-year view of Revenue shows it stood at $55.0 million in 2021, then plummeted by 46.66% to $29.3 million in 2022, then soared by 53.58% to $45.1 million in 2023, then skyrocketed by 65.98% to $74.8 million in 2024, then soared by 73.41% to $129.7 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Revenue are $129.7 million (Q4 2025), $40.0 million (Q3 2025), and $114.4 million (Q2 2025).